Abstract: The present disclosure provides a method for forming a liquid flow in a surface region of a liquid, and a method for moving a larger object in a non-contact and non-invasive manner.

Abstract: There are provided a resin composition that is suitable for the production of a flame-retardant molded article and that can provide high flame retardancy even with a small amount of flame retardant added, and a flame retardancy determination method for determining the flame retardancy of a resin composition. The resin composition of the present invention contains a thermoplastic resin, a cellulosic material, and a phosphate flame retardant and satisfies relational expressions (1) and (2) (where in expressions (1) and (2), TP, TB, and TCMP are temperatures at weight loss rate peaks in thermogravimetric analysis, TP is a temperature (° C.) at a weight loss rate peak of the thermoplastic resin, TB is a temperature (° C.) at a weight loss rate peak of the cellulosic material, and TCMP is a temperature (° C.) at a weight loss rate peak of the resin composition. When the resin composition has two weight loss rate peaks, TCMP is a temperature at a peak on a lower temperature side).

Abstract: A method implemented in a computer system includes training a network, which is obtained by unfolding an iterative algorithm for demodulation or demodulation and decoding, using a machine learning technique with a loss function that takes into account non-Gaussianity of a log-likelihood ratio (LLR) distribution calculated from an output of the network. The method further includes producing a first set of learned parameters of that iterative algorithm.

Abstract: Provided is a metal negative electrode that has an excellent repeat resistance and is excellent in charge and discharge cycle characteristics even in a high charge and discharge rate, a method for fabricating the same, and a secondary battery using the metal negative electrode. The metal negative electrode is a metal negative electrode used for a secondary battery, which includes an active material portion, a current collector, and a non-electronically conductive reaction space divider. The active material portion forms metal during charging and forms an oxidation product of the metal during discharging. The metal is used as a negative-electrode active material. The current collector is electrically connected to the active material portion. The non-electronically conductive reaction space divider is integrally formed with or connected to the current collector and/or the active material portion. The reaction space divider has a plurality of electrolyte holder portions configured to hold a liquid electrolyte.

Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

Abstract: The present disclosure provides a method of preserving corneal endothelial cells at a high cell survival rate. The present disclosure provides a method of preserving corneal endothelial cells and/or corneal endothelium-like cells, comprising preserving the corneal endothelial cells and corneal endothelium-like cells in a container with a bottom area of at least about 0.7 cm2. Accordingly to the present invention, corneal endothelial cells can be preserved at a high cell survival rate. Corneal endothelial cells preserved in this manner have functions of normal corneal endothelial cells. Such cells can also be used as cells for treating a corneal endothelial disease or the like.

Abstract: One aspect of the present invention is a nonaqueous electrolyte for an energy storage device comprising: an alkali metal salt; a first aprotic organic solvent coordinating to an alkali metal ion in the alkali metal salt, and not including a fluorine atom; a second aprotic organic solvent including a fluorine atom; and an additive comprising a polar group and a group including a fluorine atom, wherein a content of the alkali metal salt is no less than 0.9 mol/kg and less than 2 mol/kg, a content of the first aprotic organic solvent with respect to the content of the alkali metal salt in terms of a molar ratio is no less than 0.7 and no greater than 4, and a content of the second aprotic organic solvent with respect to a total amount of the first aprotic organic solvent, the second aprotic organic solvent and the additive is no less than 40% by volume.

Abstract: Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-? (TGF-?) signals and/or mitochondrial abnormalities in corneal endothelial cells. The present invention provides a drug which includes caspase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-? signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.

Abstract: The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-? (TGF-?) signal and/or extracellular matrix (ECM).

Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

Abstract: A BP detector of a wireless receiver apparatus reads a first parameter set or a second parameter set. The first parameter set includes a plurality of scaling factors and a plurality of damping factors learned together using a deep learning technique. The second parameter set includes a plurality of scaling factors and a plurality of node selection factors learned together using a deep learning technique from a memory. The BP detector executes an iterative BP algorithm that uses the first parameter set or the second parameter set in order to perform multi-user detection.

Abstract: An analytical device includes: a reaction unit into which an ion derived from a sample component is introduced; a radical generation unit that generates a radical by vacuum discharge and comprises a raw material introduction chamber into which a plasma raw material is introduced; a connection part that introduces the radical generated in the radical generation unit into a vacuum chamber, the vacuum chamber having a pressure lower than a pressure of the raw material introduction chamber and being connected to the reaction unit; and a separation unit that separates a generated ion generated by a reaction with the radical introduced via the connection part into the reaction unit according to m/z and/or ion mobility, wherein an inner diameter of a cross section of the connection part is equal to or less than 20 millimeters.

Abstract: A computer system includes at least one memory and at least one processor coupled to the at least one memory and configured to execute one or more sets of instructions. The one or more sets of instructions, when executed by the at least one processor, cause the computer system to provide virtualized radio access network functions including executing a BP algorithm and provide controller functions including adjusting the total number of iterations of the BP algorithm depending on available computing resources of the computer system.

Abstract: A BP detector of a wireless receiver apparatus reads a first parameter set or a second parameter set. The first parameter set includes a plurality of scaling factors and a plurality of damping factors learned together using a deep learning technique. The second parameter set includes a plurality of scaling factors and a plurality of node selection factors learned together using a deep learning technique from a memory. The BP detector executes an iterative BP algorithm that uses the first parameter set or the second parameter set in order to perform multi-user detection.

Abstract: A production method for a magnetic material, which is expressed by a chemical structure formula Fe(Al1-xMnx)2O4, where 0<x<1, and exhibits ferromagnetism, includes: preparing a mixed aqueous solution by dissolving, in distilled water, Fe nitrate, Al nitrate, and an oxide including Mn, the Fe nitrate, the Al nitrate, and the oxide being parent materials; preparing a metal-citric acid complex by mixing citric acid and ethylene glycol with the mixed aqueous solution; obtaining a precursor by boiling the metal-citric acid complex to a gel and drying the gel; and obtaining the magnetic material by sintering the precursor.

Abstract: An ion analyzer that generates product ions from precursor ions derived from a sample component and analyzes the product ions includes a reaction chamber (2) into which the precursor ion is introduced, a radical generation chamber (51), a material gas supply source (52) configured to introduce material gas into the radical generation chamber (51), a vacuum evacuator (57) configured to evacuate the radical generation chamber (51), a vacuum discharge unit (53) configured to generate a vacuum discharge in the radical generation chamber (51), a radical irradiation unit (54) configured to irradiate an inside of the reaction chamber (2) with radicals generated from the material gas in the radical generation chamber (51), and a separation and detection (3) configured to separate and detect product ions generated from the precursor ion by reaction with the radicals according to at least one of a mass-to-charge ratio and ion mobility.

Abstract: Provided is a drug or method for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by transforming growth factor-? (TGF-?) signals, mitochondrial abnormalities, and/or endoplasmic reticulum (ER) associated stress in corneal endothelial cells, using p38 MAP kinase inhibitors. The present invention provides a drug which includes p38 MAP kinase inhibitors, and which is for treating or preventing a condition, disorder, or disease of the corneal endothelium caused by TGF-? signals and/or mitochondrial abnormalities in corneal endothelial cells. In the preferred embodiment, the condition, disorder, or disease of the corneal endothelium is Fuchs' corneal endothelial dystrophy.

Abstract: The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.

Abstract: The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing.

Abstract: The inventors have found that VCP inhibitors protect corneal endothelial cells and corneal epithelial cells. Accordingly, the disclosure provides a composition for protecting a cornea comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof. In another aspect the disclosure provides a composition for treating and/or preventing a corneal disease comprising a compound of formula (I). In a further aspect the disclosure provides a composition for ocular irrigation comprising a compound of formula (I). In a still further aspect the disclosure provides a composition for preserving a corneal graft comprising a compound of formula (I).